KYTX
Kyverna Therapeutics, Inc. Common Stock
NASDAQ: KYTX · HEALTHCARE · BIOTECHNOLOGY
$9.47
+2.82% today
Updated 2026-05-06
Market cap
$557.48M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.64
Dividend yield
—
52W range
$2 – $14
Volume
0.9M
Kyverna Therapeutics, Inc. Common Stock (KYTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $-22.16M | $-36.11M | $-52.41M | $-114.25M | $-153.71M |
| Capital expenditures | $1.29M | $768000.00 | $621000.00 | $2.21M | $5000.00 |
| Depreciation | — | — | — | — | — |
| Stock-based comp | $7.25M | $929000.00 | $2.22M | $8.36M | $10.08M |
| Free cash flow | $-23.44M | $-36.88M | $-53.03M | $-116.45M | $-153.72M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt repayment | — | — | — | — | — |
| Net change in cash | — | — | — | — | — |